Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mithoefer

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|September 25, 2004
Ecstasy use-Parkinson's disease link tenuousLisa Jerome, Rick Doblin, Michael Mithoefer
Science (New York, N.Y.)|June 7, 2003
MDMA ("ecstasy") and neurotoxicityMichael Mithoefer, Lisa Jerome, Richard Doblin
Frontiers in Psychiatry|December 21, 2023
Group psychedelic therapy: empirical estimates of cost-savings and improved accessElliot Marseille, Christopher S Stauffer, Manish Agrawal, et al.
Journal of Psychiatric Research|March 10, 2022
MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSDTimothy D Brewerton, Julie B Wang, Adele Lafrance, et al.
Frontiers in Psychology|November 19, 2024
The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSDKelley C O'Donnell, Lauren Okano, Michael Alpert, et al.
Plos One|January 10, 2024
Effects of MDMA-assisted therapy for PTSD on self-experienceBessel A van der Kolk, Julie B Wang, Rachel Yehuda, et al.
Frontiers in Psychiatry|January 30, 2023
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorderS Parker Singleton, Julie B Wang, Michael Mithoefer, et al.
Nature Medicine|October 7, 2024
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
Nature Medicine|September 14, 2023
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
JAMA Network Open|June 4, 2024
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus StatementAmy L McGuire, I Glenn Cohen, Dominic Sisti, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Movement Disorders : Official Journal of the Movement Disorder Society|September 25, 2004
Ecstasy use-Parkinson's disease link tenuousLisa Jerome, Rick Doblin, Michael Mithoefer
Science (New York, N.Y.)|June 7, 2003
MDMA ("ecstasy") and neurotoxicityMichael Mithoefer, Lisa Jerome, Richard Doblin
Frontiers in Psychiatry|December 21, 2023
Group psychedelic therapy: empirical estimates of cost-savings and improved accessElliot Marseille, Christopher S Stauffer, Manish Agrawal, et al.
Journal of Psychiatric Research|March 10, 2022
MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSDTimothy D Brewerton, Julie B Wang, Adele Lafrance, et al.
Frontiers in Psychology|November 19, 2024
The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSDKelley C O'Donnell, Lauren Okano, Michael Alpert, et al.
Plos One|January 10, 2024
Effects of MDMA-assisted therapy for PTSD on self-experienceBessel A van der Kolk, Julie B Wang, Rachel Yehuda, et al.
Frontiers in Psychiatry|January 30, 2023
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorderS Parker Singleton, Julie B Wang, Michael Mithoefer, et al.
Nature Medicine|October 7, 2024
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
Nature Medicine|September 14, 2023
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
JAMA Network Open|June 4, 2024
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus StatementAmy L McGuire, I Glenn Cohen, Dominic Sisti, et al.
Pageof 2